Literature DB >> 18595141

Construction and expression of eukaryotic plasmids containing lamivudine-resistant or wild-type strains of Hepatitis B Virus genotype C.

Wei-Zhen Xu1, Yong Fang, Di Li, Yan Wang, Qing-Long Shang, Gui-Qiu Li, Xu Teng, Hong-Xi Gu.   

Abstract

AIM: To construct eukaryotic expression plasmids of full-length Hepatitis B Virus (HBV) genotype C genome, which contain lamivudine-resistant mutants (YIDD, YVDD) or wild-type strain (YMDD), and to observe the expression of HBV DNA and antigens [hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg)] of the recombinant plasmids in HepG2 cells.
METHODS: Three HBV full-length genomes were amplified from the plasmids pMD18T-HBV/YIDD, pMD18T-HBV/YVDD and pMD18T-HBV/YMDD, using PCR. Three recombinant plasmids were generated by inserting each of the PCR products into the eukaryotic expression vector pcDNA3.1 (+), between the EcoRI and HindIII sites. After being characterized by restriction endonuclease digestion, and DNA sequence analysis, the recombinant plasmids were transfected into HepG2 cells. At 48 and 72 h post-transfection, the levels of intracellular viral DNA replication were detected by real-time PCR, and the expression of HBsAg and HBeAg in the cell culture supernatant was determined by ELISA.
RESULTS: Restriction endonuclease digestion and DNA sequence analysis confirmed that the three recombinant plasmids were correctly constructed. After transfecting the plasmids into HepG2 cells, high levels of intracellular viral DNA replication were observed, and HBsAg and HBeAg were secreted into the cell culture supernatant.
CONCLUSION: Eukaryotic expression plasmids pcDNA3.1 (+)-HBV/YIDD, pcDNA3.1 (+)-HBV/YVDD or pcDNA3.1 (+)-HBV/YMDD, which contained HBV genotype C full-length genome, were successfully constructed. After transfection into HepG2 cells, the recombinant plasmids efficiently expressed HBV DNA, HBsAg and HBeAg. Our results provide an experimental basis for the further study of HBV lamivudine-resistant mutants.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18595141      PMCID: PMC2719237          DOI: 10.3748/wjg.14.3733

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  28 in total

1.  Dynamics of hepatitis B virus resistance to lamivudine.

Authors:  Coralie Pallier; Laurent Castéra; Alexandre Soulier; Christophe Hézode; Patrice Nordmann; Daniel Dhumeaux; Jean-Michel Pawlotsky
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

2.  A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness.

Authors:  L Stuyver; S De Gendt; C Van Geyt; F Zoulim; M Fried; R F Schinazi; R Rossau
Journal:  J Gen Virol       Date:  2000-01       Impact factor: 3.891

3.  Stable HepG2- and Huh7-based human hepatoma cell lines for efficient regulated expression of infectious hepatitis B virus.

Authors:  Dianxing Sun; Michael Nassal
Journal:  J Hepatol       Date:  2006-07-07       Impact factor: 25.083

4.  Fatal liver failure caused by reactivation of lamivudine-resistant hepatitis B virus: a case report.

Authors:  Yuka Suzuki; Hiroshi Yotsuyanagi; Chiaki Okuse; Yoshihiko Nagase; Hideaki Takahashi; Kyoji Moriya; Michihiro Suzuki; Kazuhiko Koike; Shiro Iino; Fumio Itoh
Journal:  World J Gastroenterol       Date:  2007-02-14       Impact factor: 5.742

5.  Influence of hepatitis B virus genotypes on the intra- and extracellular expression of viral DNA and antigens.

Authors:  Masaya Sugiyama; Yasuhito Tanaka; Takanobu Kato; Etsuro Orito; Kiyoaki Ito; Subrat K Acharya; Robert G Gish; Anna Kramvis; Takashi Shimada; Namiki Izumi; Masahiko Kaito; Yuzo Miyakawa; Masashi Mizokami
Journal:  Hepatology       Date:  2006-10       Impact factor: 17.425

6.  Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.

Authors:  Marie-Noëlle Brunelle; Anne-Carole Jacquard; Christian Pichoud; David Durantel; Sandra Carrouée-Durantel; Jean-Pierre Villeneuve; Christian Trépo; Fabien Zoulim
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

7.  Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.

Authors:  M I Allen; M Deslauriers; C W Andrews; G A Tipples; K A Walters; D L Tyrrell; N Brown; L D Condreay
Journal:  Hepatology       Date:  1998-06       Impact factor: 17.425

8.  Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.

Authors:  X P Pan; L J Li; W B Du; M W Li; H C Cao; J F Sheng
Journal:  J Viral Hepat       Date:  2007-11       Impact factor: 3.728

9.  YMDD mutations and genotypes of hepatitis B virus in northern China.

Authors:  Di Li; Hong-Xi Gu; Shu-Yun Zhang; Zhao-Hua Zhong; Min Zhuang; Toshio Hattori
Journal:  Jpn J Infect Dis       Date:  2006-02       Impact factor: 1.362

10.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

Authors:  C L Lai; R N Chien; N W Leung; T T Chang; R Guan; D I Tai; K Y Ng; P C Wu; J C Dent; J Barber; S L Stephenson; D F Gray
Journal:  N Engl J Med       Date:  1998-07-09       Impact factor: 91.245

View more
  1 in total

1.  Effect of hepato-toxins in the acceleration of hepatic fibrosis in hepatitis B mice.

Authors:  Suchithra Poilil Surendran; Reju George Thomas; Myeong Ju Moon; Rayoung Park; Doo Hyun Kim; Kyun Hwan Kim; Yong Yeon Jeong
Journal:  PLoS One       Date:  2020-05-19       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.